B. Barón

2.0k total citations
28 papers, 1.4k citations indexed

About

B. Barón is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, B. Barón has authored 28 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 8 papers in Surgery. Recurrent topics in B. Barón's work include Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (4 papers). B. Barón is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (4 papers). B. Barón collaborates with scholars based in Belgium, Netherlands and France. B. Barón's co-authors include J. Wils, Patrick Schöffski, P. Rougier, Olivier Chinot, Nathan De Beule, Werner Scheithauer, David Cunningham, Enrique Aranda, Francesco Di Costanzo and Bengt Glimelius and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and Annals of Oncology.

In The Last Decade

B. Barón

28 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Barón Belgium	17	649	543	356	291	275	28	1.4k
Garth D. Nelson United States	16	1.1k 1.6×	280 0.5×	533 1.5×	143 0.5×	716 2.6×	42	1.7k
Virginie Lucas United States	13	779 1.2×	235 0.4×	103 0.3×	119 0.4×	429 1.6×	24	1.1k
David Rinaldi United States	19	1.3k 2.0×	867 1.6×	302 0.8×	174 0.6×	97 0.4×	38	1.9k
Giuseppe Fornarini Italy	22	597 0.9×	562 1.0×	305 0.9×	101 0.3×	74 0.3×	125	1.3k
Robert M. OʼBryan United States	18	960 1.5×	636 1.2×	301 0.8×	64 0.2×	216 0.8×	44	1.5k
Dwight H. Owen United States	22	1.4k 2.1×	651 1.2×	165 0.5×	126 0.4×	94 0.3×	110	1.9k
Sandra J. Casak United States	18	455 0.7×	215 0.4×	189 0.5×	78 0.3×	148 0.5×	32	1.0k
Yihebali Chi China	16	1.5k 2.3×	817 1.5×	378 1.1×	45 0.2×	238 0.9×	67	2.0k
Martha Donoghue United States	16	696 1.1×	400 0.7×	154 0.4×	57 0.2×	163 0.6×	27	1.2k
Jae‐Cheol Jo South Korea	20	682 1.1×	300 0.6×	124 0.3×	220 0.8×	469 1.7×	134	1.4k

Countries citing papers authored by B. Barón

Since Specialization

Citations

This map shows the geographic impact of B. Barón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Barón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Barón more than expected).

Fields of papers citing papers by B. Barón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Barón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Barón. The network helps show where B. Barón may publish in the future.

Co-authorship network of co-authors of B. Barón

This figure shows the co-authorship network connecting the top 25 collaborators of B. Barón. A scholar is included among the top collaborators of B. Barón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Barón. B. Barón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stenzl, Arnulf, et al.. (2016). Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial. Annals of Oncology. 27. vi262–vi262. 3 indexed citations

Nitti, Donato, J. Wils, George Fountzilas, et al.. (2005). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Annals of Oncology. 17(2). 262–269. 67 indexed citations

Giaccone, Giuseppe, Egbert F. Smit, Maja J.A. de Jonge, et al.. (2004). Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer. European Journal of Cancer. 40(5). 667–672. 27 indexed citations

Smyth, J F, Ahmad Awada, Christian Dittrich, et al.. (2004). Phase II study of E7070 in patients with metastatic melanoma. Annals of Oncology. 16(1). 158–161. 46 indexed citations

Jeziorski, Krzysztof, D. J. Th. Wagener, Jean‐Luc Van Laethem, et al.. (2004). Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group. European Journal of Cancer. 40(14). 2077–2081. 17 indexed citations

Jonge, Maja J.A. de, J P Droz, Luis Paz‐Ares, et al.. (2004). Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Investigational New Drugs. 22(3). 329–333. 6 indexed citations

Schöffski, P., P. Fumoleau, Mario Campone, et al.. (2004). Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Annals of Oncology. 15(12). 1816–1824. 72 indexed citations

Punt, Cornelis J. A., Maja J.A. de Jonge, S. Monfardini, et al.. (2004). RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. European Journal of Cancer. 40(9). 1332–1334. 12 indexed citations

Duffaud, Florence, Markus Borner, P. Chollet, et al.. (2004). Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. European Journal of Cancer. 40(18). 2748–2752. 30 indexed citations

10.

Bent, Martin J. van den, Wolfgang Grisold, Didier Frappaz, et al.. (2003). European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Annals of Oncology. 14(12). 1732–1734. 32 indexed citations

11.

Wils, J., G.H. Blijham, Jacques De Grève, et al.. (2003). High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer. European Journal of Cancer. 39(3). 346–352. 5 indexed citations

12.

Bent, Martin J. van den, Olivier Chinot, Willem Boogerd, et al.. (2003). Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Annals of Oncology. 14(4). 599–602. 123 indexed citations

13.

Piccart, Martine, K. Bertelsen, Gavin Stuart, et al.. (2002). Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer. Annals of Oncology. 5 indexed citations

14.

Conroy, Thierry, Pierre Étienne, Antoine Adenis, et al.. (2002). Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Annals of Oncology. 13(5). 721–729. 54 indexed citations

15.

Köhne, C.-H., David Cunningham, Francesco Di Costanzo, et al.. (2002). Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Annals of Oncology. 13(2). 308–317. 356 indexed citations

16.

Wagener, D. J. Th., J. Wils, T.C. Kok, et al.. (2002). Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. European Journal of Cancer. 38(5). 648–653. 21 indexed citations

17.

Sylvester, Richard, M. van Glabbeke, Laurence Collette, et al.. (2002). Statistical methodology of phase III cancer clinical trials: advances and future perspectives. European Journal of Cancer. 38. 162–168. 9 indexed citations

18.

Wils, J., Donato Nitti, George Fountzilas, et al.. (2002). Randomized phase III studies of adjuvant chemotherapy with FAMTX or FEMTX in resected gastric cancer. Pooled results of studies from the EORTC GI-group and the ICCG. Research Padua Archive (University of Padua). 3 indexed citations

19.

Wobbes, Th., B. Barón, B Paillot, et al.. (2001). Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. European Journal of Cancer. 37(4). 470–477. 30 indexed citations

20.

Localio, S. Arthur & B. Barón. (1973). Abdomino-Transsacral Resection and Anastomosis for Mid-Rectal Cancer. Annals of Surgery. 178(4). 540–546. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact